UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2017
REGENXBIO INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-37553 | 47-1851754 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
9600 Blackwell Road, Suite 210 Rockville, Maryland |
20850 | |||
(Address of principal executive offices) | (Zip Code) |
(240) 552-8181
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. | Other Events. |
On April 26, 2017, REGENXBIO Inc. (the Company) issued a press release announcing that the underwriters of its previously announced public offering of common stock, which initially closed on March 27, 2017, have exercised their option to purchase an additional 555,000 shares of the Companys common stock. The aggregate net proceeds to the Company in connection with the offering are expected to be approximately $81.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit No. |
Description | |
99.1 | REGENXBIO Inc. Press Release dated April 26, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENXBIO INC. | ||||||
Date: April 26, 2017 | By: | /s/ Patrick J. Christmas II | ||||
Patrick J. Christmas II | ||||||
Senior Vice President, General Counsel |
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | REGENXBIO Inc. Press Release dated April 26, 2017. |
EXHIBIT 99.1
REGENXBIO Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares
ROCKVILLE, Md., April 26, 2017 REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the underwriters of REGENXBIOs public offering of common stock have purchased an additional 555,000 shares of common stock at a price of $20.50 per share, before deducting the underwriting discount, in connection with the exercise in full of their option to purchase additional shares. As a result of the underwriters exercise of their option to purchase additional shares, the total number of shares of REGENXBIO common stock sold in the offering increased to 4,255,000 shares, and the total gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, increased to approximately $87.2 million.
Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. acted as joint book-running managers. Chardan Capital Markets, LLC acted as co-manager of the offering.
The securities described above were offered by REGENXBIO pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (the SEC) on January 6, 2017. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SECs website at www.sec.gov. Copies of the final prospectus supplement relating to this offering may be obtained from: Morgan Stanley at Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014; or BofA Merrill Lynch at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIOs NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, REGENXBIOs offering of its common stock. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of REGENXBIOs development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Meaningful factors which could cause actual results to differ include, but are not limited to, the timing of enrollment, commencement and completion of REGENXBIOs clinical trials; the timing and success of preclinical studies and clinical trials conducted by REGENXBIO and its development partners; the ability to obtain and maintain regulatory approval of REGENXBIOs product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing REGENXBIOs product candidates; REGENXBIOs ability to obtain and maintain intellectual property protection for REGENXBIOs product candidates and technology; REGENXBIOs growth strategies; REGENXBIOs competition; trends and challenges in REGENXBIOs business and the markets in which REGENXBIO operates; REGENXBIOs ability to attract or retain key personnel; the size and growth of the potential markets for REGENXBIOs product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of REGENXBIOs product candidates; REGENXBIOs ability to establish and maintain development partnerships; REGENXBIOs expenses and revenue; regulatory developments in the United States and foreign countries; the sufficiency of REGENXBIOs cash resources and needs for additional financing; and other factors discussed in the Risk Factors and Managements Discussion and Analysis of
Financial Condition and Results of Operations sections of REGENXBIOs Annual Report on Form 10-K for the year ended December 31, 2016. In addition to the risks described above and in REGENXBIOs filings with the SEC, other unknown or unpredictable factors also could affect REGENXBIOs results. There can be no assurance that the actual results or developments anticipated by REGENXBIO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, REGENXBIO. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. REGENXBIO cautions investors not to rely too heavily on the forward-looking statements REGENXBIO makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). REGENXBIO undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Investors
Heather Savelle, 646-395-3734
heather@argotpartners.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com